First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph(+)) acute lymphoblastic leukemia

The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome–positive (Ph(+)) acute lymphoblastic leukemia (ALL). Dasatinib has significant clinical activity in patients with imatinib resistance. We examined the efficacy and safety of comb...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ravandi, Farhad, O'Brien, Susan, Thomas, Deborah, Faderl, Stefan, Jones, Dan, Garris, Rebecca, Dara, Samuel, Jorgensen, Jeffrey, Kebriaei, Partow, Champlin, Richard, Borthakur, Gautam, Burger, Jan, Ferrajoli, Alessandra, Garcia-Manero, Guillermo, Wierda, William, Cortes, Jorge, Kantarjian, Hagop
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2010
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081177/
https://ncbi.nlm.nih.gov/pubmed/20466853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-12-261586
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars